Drug Reference
Drug Reference

Heart Failure GDMT

Guideline-directed medical therapy for HFrEF and HFpEF — the four pillars, dosing, titration, and landmark trial evidence

HFrEF HFpEF Quadruple Therapy Titration
Updated: March 2026
1

The Four Pillars of HFrEF Therapy

Modern heart failure management for patients with reduced ejection fraction (HFrEF, LVEF ≤40%) is anchored on four foundational drug classes, each of which independently reduces mortality and hospitalization. The 2022 AHA/ACC/HFSA guidelines give a Class I recommendation for all four pillars in symptomatic HFrEF patients.

The concept of quadruple therapy emerged from the recognition that each pillar works through a distinct neurohormonal or metabolic pathway: RAASi (renin-angiotensin-aldosterone), beta-blockers (sympathetic nervous system), MRAs (aldosterone and fibrosis), and SGLT2 inhibitors (sodium-glucose cotransport and cardiorenal axis). Combining all four provides additive and potentially synergistic benefit.

THE FOUR PILLARS OF HFrEF THERAPY
  1. RAASi — ARNI (preferred), ACEi, or ARB: Neurohormonal blockade of the renin-angiotensin system
  2. Beta-blocker — Carvedilol, metoprolol succinate, or bisoprolol: Sympathetic antagonism and reverse remodeling
  3. MRA — Spironolactone or eplerenone: Aldosterone blockade, anti-fibrotic effects
  4. SGLT2 inhibitor — Dapagliflozin or empagliflozin: Cardiorenal protection across the EF spectrum

Simultaneous vs. Sequential Initiation

Traditionally, GDMT was started one agent at a time ("start low, go slow"), with each drug uptitrated to target dose before adding the next. This approach delays full therapy by months. The STRONG-HF trial (2022) demonstrated that rapid, simultaneous initiation and uptitration of all four pillars within 2 weeks of discharge was safe, well-tolerated, and reduced 180-day heart failure readmission by 34% compared to usual care. Close follow-up (visits at 1, 2, 3, and 6 weeks) was essential to the safety of rapid titration.

Current expert consensus favors early initiation of all four pillars at low doses, with subsequent uptitration to target doses over 4-6 weeks. The priority is getting all four classes on board quickly, even at starting doses, rather than maximizing one class before starting the next.

Pillar Landmark Trial Mortality Reduction NNT (Mortality) NNT (HF Hosp.)
RAASi (ARNI) PARADIGM-HF 20% relative reduction vs. enalapril 36 over 27 months 21 over 27 months
RAASi (ACEi) CONSENSUS / SOLVD 27-40% relative reduction vs. placebo 7 (CONSENSUS, severe HF) 4.5 (SOLVD)
Beta-blocker MERIT-HF / COPERNICUS 34-35% relative reduction 26 (MERIT-HF, 1 yr) 18 (COPERNICUS)
MRA RALES / EMPHASIS-HF 24-30% relative reduction 9 (RALES, 2 yr) 11 (EMPHASIS-HF)
SGLT2i DAPA-HF / EMPEROR-Reduced 13-18% relative reduction (CV death) 45 (DAPA-HF, 18 mo) 21 (DAPA-HF)
Clinical Pearl: The combined benefit of all four pillars at target doses has been estimated to extend life by 6-8 years compared to no therapy in a 55-year-old with HFrEF. Even at starting doses, all four classes together provide more mortality benefit than maximizing any single class alone. Prioritize getting all four on board over maximizing individual drug doses.
2

RAASi: ARNI, ACEi, ARB

Renin-angiotensin-aldosterone system inhibitors (RAASi) form the oldest and most extensively studied pillar of HFrEF therapy. Three subclasses are available: angiotensin receptor-neprilysin inhibitors (ARNI), angiotensin-converting enzyme inhibitors (ACEi), and angiotensin receptor blockers (ARB). Current guidelines recommend ARNI as the preferred first-line agent over ACEi or ARB, based on the superiority demonstrated in PARADIGM-HF.

Sacubitril/Valsartan (ARNI)

Sacubitril/valsartan combines an ARB (valsartan) with a neprilysin inhibitor (sacubitril), which increases levels of natriuretic peptides (BNP, ANP) and other vasoactive substances. In PARADIGM-HF (n=8,442), sacubitril/valsartan reduced the primary composite of cardiovascular death or HF hospitalization by 20% compared to enalapril 10 mg BID (HR 0.80, p<0.001). The trial was stopped early for overwhelming benefit.

Key prescribing points: A 36-hour washout period is mandatory when switching from an ACEi to ARNI, to reduce angioedema risk. No washout is needed when switching from an ARB. Monitor blood pressure and potassium at each uptitration visit. Sacubitril raises BNP levels (neprilysin degrades BNP), so use NT-proBNP (not BNP) to monitor HF status in patients on ARNI.

ACE Inhibitors

ACE inhibitors were the first RAASi shown to reduce mortality in HFrEF. CONSENSUS (1987) demonstrated a 40% reduction in 6-month mortality in severe HF (NYHA IV) with enalapril. SOLVD-Treatment (1991) showed a 16% reduction in all-cause mortality in mild-moderate HF. These trials established the foundation for all subsequent GDMT research.

Angiotensin Receptor Blockers

ARBs are recommended as an alternative for patients who are ACEi-intolerant (typically due to cough). Val-HeFT showed valsartan reduced the combined endpoint of mortality and morbidity by 13%. CHARM-Alternative demonstrated candesartan reduced CV death or HF hospitalization by 23% in ACEi-intolerant patients. ARBs are not considered equivalent to ARNI and should be used only when ARNI and ACEi are not tolerated.

Drug Class Starting Dose Target Dose Key Trial Evidence
Sacubitril/valsartan ARNI 24/26 mg BID 97/103 mg BID PARADIGM-HF: 20% reduction in CV death/HHF vs. enalapril
Enalapril ACEi 2.5 mg BID 10-20 mg BID CONSENSUS: 40% mortality reduction (NYHA IV); SOLVD: 16% reduction
Lisinopril ACEi 2.5-5 mg daily 20-40 mg daily ATLAS: higher doses superior to lower doses
Ramipril ACEi 1.25-2.5 mg BID 5 mg BID AIRE: 27% mortality reduction post-MI with HF
Losartan ARB 25-50 mg daily 150 mg daily HEAAL: higher dose superior to lower dose
Valsartan ARB 40 mg BID 160 mg BID Val-HeFT: 13% reduction in combined mortality/morbidity
Candesartan ARB 4-8 mg daily 32 mg daily CHARM-Alternative: 23% reduction in CV death/HHF

Contraindications

  • Pregnancy (absolute — teratogenic, Category X)
  • Bilateral renal artery stenosis — risk of acute kidney injury
  • History of angioedema with ACEi (can use ARB cautiously; ARNI contraindicated with ACEi-related angioedema)
  • Hyperkalemia (K+ >5.5 mEq/L) — correct before initiation
  • Symptomatic hypotension (SBP <90 mmHg) — relative contraindication; consider lower starting doses
  • Concurrent ACEi + ARNI — never combine (angioedema risk)
Clinical Pearl: The ARNI-first approach is now preferred over starting with an ACEi and later switching. The PIONEER-HF trial showed that de novo initiation of sacubitril/valsartan in stabilized hospitalized patients was safe and resulted in greater NT-proBNP reduction than enalapril. Start ARNI directly in new HFrEF patients without requiring prior ACEi tolerance, unless contraindicated. Use the 24/26 mg BID starting dose for ACEi-naive patients.
3

Beta-Blockers

Beta-blockers reverse the toxic effects of chronic sympathetic activation in HFrEF — reducing heart rate, myocardial oxygen demand, and arrhythmia risk while promoting reverse remodeling. However, not all beta-blockers are equal. Only three agents have robust evidence for mortality reduction in HFrEF: carvedilol, metoprolol succinate (extended-release), and bisoprolol.

Atenolol and short-acting metoprolol tartrate have NOT been shown to reduce mortality in HFrEF and should not be used as substitutes. Nebivolol showed benefit in an elderly HF population (SENIORS trial) but is not included in guideline Class I recommendations.

Evidence Base

  • COPERNICUS (carvedilol): 35% reduction in all-cause mortality in severe HF (NYHA III-IV, LVEF <25%). Also improved symptoms and reduced hospitalizations. Carvedilol provides additional alpha-1 blockade (vasodilation) and antioxidant properties.
  • MERIT-HF (metoprolol succinate CR/XL): 34% reduction in all-cause mortality in NYHA II-III HF. The extended-release formulation provides stable 24-hour beta-blockade.
  • CIBIS-II (bisoprolol): 34% reduction in all-cause mortality in NYHA III-IV HF. Most beta-1 selective of the three evidence-based agents.

Titration Principles

Start at the lowest dose and uptitrate every 2 weeks (minimum) as tolerated, targeting the heart rate and trial-proven target dose. Monitor for bradycardia (HR <50), hypotension, fatigue, and worsening HF symptoms. During an acute decompensation, reduce the dose if needed but do not abruptly discontinue — abrupt withdrawal can trigger rebound sympathetic surge and hemodynamic deterioration.

Drug Starting Dose Target Dose Uptitration Key Trial
Carvedilol 3.125 mg BID 25 mg BID (<85 kg) or 50 mg BID (≥85 kg) Double every 2 weeks COPERNICUS: 35% mortality reduction
Metoprolol succinate (CR/XL) 12.5-25 mg daily 200 mg daily Double every 2 weeks MERIT-HF: 34% mortality reduction
Bisoprolol 1.25 mg daily 10 mg daily Double every 2 weeks CIBIS-II: 34% mortality reduction
Clinical Pearl: Metoprolol tartrate (short-acting, e.g., Lopressor) is NOT the same as metoprolol succinate (extended-release, e.g., Toprol-XL). Only metoprolol succinate CR/XL has proven mortality benefit in HFrEF. This is one of the most common prescribing errors in heart failure management. Always verify the formulation. Similarly, atenolol — despite being widely prescribed — has no HFrEF mortality data and should be switched to one of the three evidence-based agents.
4

Mineralocorticoid Receptor Antagonists (MRAs)

MRAs block the effects of aldosterone on the distal nephron and cardiovascular system. Beyond their diuretic properties, MRAs exert potent anti-fibrotic effects on the myocardium and vasculature, reduce cardiac remodeling, and decrease the risk of sudden cardiac death. They are recommended for all HFrEF patients with NYHA II-IV symptoms who have adequate renal function and potassium levels.

Spironolactone

The RALES trial (1999) demonstrated a 30% reduction in all-cause mortality with spironolactone 25-50 mg daily added to background ACEi and loop diuretic therapy in severe HF (NYHA III-IV, LVEF ≤35%). The trial was stopped early due to overwhelming benefit. Gynecomastia and breast tenderness occurred in approximately 10% of men due to spironolactone's non-selective binding to androgen and progesterone receptors.

Eplerenone

EMPHASIS-HF (2011) showed eplerenone 25-50 mg daily reduced the composite of CV death or HF hospitalization by 37% in mild HF (NYHA II, LVEF ≤30%). Eplerenone is selective for the mineralocorticoid receptor and has a significantly lower rate of gynecomastia (<1%) compared to spironolactone. It is the preferred agent for men experiencing anti-androgenic side effects.

Finerenone

Finerenone is a non-steroidal, selective MRA with distinct pharmacologic properties. It was studied primarily in diabetic kidney disease (FIDELIO-DKD, FIGARO-DKD), where it reduced cardiovascular events and kidney disease progression. It carries a lower risk of hyperkalemia than steroidal MRAs. Its role in primary HFrEF management is still emerging, with dedicated HF trials ongoing (FINEARTS-HF showed benefit in HFpEF).

Monitoring

  • Check K+ and creatinine within 1 week of initiation, then at 1 month, then every 3 months
  • If K+ rises to 5.0-5.5 mEq/L, reduce dose (e.g., spironolactone 25 mg to 12.5 mg daily or every other day)
  • If K+ exceeds 5.5 mEq/L, hold MRA and recheck in 72 hours
  • Avoid or use extreme caution if eGFR <30 mL/min/1.73m²
Drug Starting Dose Target Dose Key Trial Notable Side Effects
Spironolactone 12.5-25 mg daily 25-50 mg daily RALES: 30% mortality reduction (severe HF) Gynecomastia (~10%), hyperkalemia
Eplerenone 25 mg daily 50 mg daily EMPHASIS-HF: 37% reduction in CV death/HHF (mild HF) Hyperkalemia (lower gynecomastia risk)
Finerenone 10 mg daily 20 mg daily FIDELIO-DKD / FIGARO-DKD (CKD+DM); FINEARTS-HF (HFpEF) Hyperkalemia (lower risk), hypotension
GYNECOMASTIA MANAGEMENT

If a male patient develops breast tenderness or gynecomastia on spironolactone, switch to eplerenone at an equivalent dose (spironolactone 25 mg → eplerenone 25-50 mg). Eplerenone's selectivity for the mineralocorticoid receptor avoids anti-androgenic and progestational effects. Do not discontinue MRA therapy altogether, as the mortality benefit is substantial.

5

SGLT2 Inhibitors

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the newest pillar of HF GDMT and the only class with demonstrated benefit across the entire ejection fraction spectrum — both HFrEF and HFpEF. Originally developed as glucose-lowering agents for type 2 diabetes, their cardiovascular and renal benefits are independent of glycemic status and equally robust in non-diabetic patients.

Evidence in HFrEF

DAPA-HF (2019): Dapagliflozin 10 mg daily reduced the composite of worsening HF or CV death by 26% (HR 0.74) vs. placebo in HFrEF patients, with or without diabetes. EMPEROR-Reduced (2020): Empagliflozin 10 mg daily reduced the same composite by 25% (HR 0.75). Both trials showed consistent benefit regardless of background GDMT, diabetes status, or baseline NT-proBNP.

Evidence in HFpEF

EMPEROR-Preserved (2021): Empagliflozin reduced the composite of CV death or HF hospitalization by 21% (HR 0.79) in HFpEF patients (LVEF >40%). This was the first trial to show clear benefit for any drug class in HFpEF — a population that had been resistant to all prior pharmacologic interventions. DELIVER (2022) confirmed similar benefit with dapagliflozin in HFmrEF/HFpEF (LVEF >40%), with a 18% reduction in the composite endpoint.

Practical Prescribing

  • Fixed dose, no titration: Both agents are given at 10 mg once daily with no dose adjustment needed
  • Cardiorenal protection: SGLT2 inhibitors slow eGFR decline and reduce renal endpoints (DAPA-CKD, EMPA-KIDNEY)
  • Initial eGFR dip: A 10-15% drop in eGFR in the first 2 weeks is expected (hemodynamic, not structural) and should not prompt discontinuation
  • Can initiate down to eGFR ~20 mL/min/1.73m² for HF indication (cardiac benefit persists even when glucosuric effect is minimal)
  • No hypoglycemia risk in non-diabetics (mechanism depends on filtered glucose load)
Drug Dose HFrEF Evidence HFpEF Evidence Key Notes
Dapagliflozin 10 mg daily (fixed) DAPA-HF: 26% reduction in worsening HF/CV death DELIVER: 18% reduction in CV death/HHF Benefit regardless of diabetes status; also shown in CKD (DAPA-CKD)
Empagliflozin 10 mg daily (fixed) EMPEROR-Reduced: 25% reduction in worsening HF/CV death EMPEROR-Preserved: 21% reduction in CV death/HHF First drug to show HFpEF benefit; also renal protection (EMPA-KIDNEY)

Safety Monitoring

  • Genital mycotic infections: ~5-6% incidence; counsel patients on hygiene; treat with topical antifungals if occurs
  • Urinary tract infections: Modest increase; standard treatment, no need to discontinue SGLT2i
  • Euglycemic DKA: Rare (<0.1%) but serious; suspect in any patient on SGLT2i with nausea/vomiting and metabolic acidosis despite normal blood glucose. More common with type 1 diabetes (not indicated), perioperative periods, and ketogenic diets
  • Volume depletion: Osmotic diuresis may require loop diuretic dose reduction; monitor weight and orthostatic symptoms
Clinical Pearl: SGLT2 inhibitors are the simplest pillar to initiate — fixed dose, no titration, no potassium monitoring, no blood pressure titration concern in most patients, and benefit regardless of diabetes status. Many experts now recommend starting SGLT2i first (or simultaneously with other pillars) because of their excellent tolerability and the absence of uptitration requirements. They can be started even during a hospitalization for acute HF once the patient is hemodynamically stable.
6

Adjunctive Therapies & Titration Strategy

Beyond the four foundational pillars, several additional agents have proven roles in specific HFrEF subpopulations or as add-on therapy when symptoms persist despite optimized quadruple therapy.

Hydralazine/Isosorbide Dinitrate

The A-HeFT trial demonstrated a 43% reduction in mortality with fixed-dose hydralazine 75 mg/isosorbide dinitrate 40 mg TID (given as BiDil) when added to background neurohormonal therapy in self-identified Black patients with NYHA III-IV HF. This combination is also recommended for patients of any race who cannot tolerate ACEi, ARB, or ARNI (e.g., severe renal insufficiency, angioedema). Target dose: hydralazine 75 mg / isosorbide dinitrate 40 mg TID.

Ivabradine

Ivabradine selectively inhibits the If ("funny") current in the sinoatrial node, reducing heart rate without affecting contractility or blood pressure. The SHIFT trial showed a 18% reduction in the composite of CV death or HF hospitalization in patients with LVEF ≤35%, sinus rhythm, and resting HR ≥70 bpm despite maximally tolerated beta-blocker therapy. Dose: start 5 mg BID, titrate to 7.5 mg BID. It is contraindicated in atrial fibrillation and in patients not in sinus rhythm.

Vericiguat

Vericiguat is a soluble guanylate cyclase (sGC) stimulator that enhances the NO-sGC-cGMP pathway. The VICTORIA trial demonstrated a 10% relative reduction in CV death or HF hospitalization in patients with HFrEF (LVEF <45%) and a recent worsening HF event (hospitalization within 6 months or IV diuretic use within 3 months). It is positioned as add-on therapy in high-risk patients with persistent symptoms despite optimized GDMT. Dose: start 2.5 mg daily, uptitrate every 2 weeks to 5 mg then 10 mg daily.

Digoxin

The DIG trial (1997) established that digoxin reduces HF hospitalizations but does not reduce mortality. It remains useful for symptom management and rate control in HFrEF patients with atrial fibrillation. Target serum level: 0.5-0.9 ng/mL (levels >1.0 associated with increased mortality). Dose adjustment is required for renal impairment.

Loop Diuretics

Loop diuretics (furosemide, bumetanide, torsemide) are essential for symptom management and decongestion but have no proven mortality benefit. They should be used at the lowest dose needed to maintain euvolemia. Torsemide has better oral bioavailability and a longer half-life than furosemide. The TRANSFORM-HF trial showed no significant difference in all-cause mortality between furosemide and torsemide.

IV Iron Replacement

Iron deficiency (ferritin <100 ng/mL, or ferritin 100-300 with TSAT <20%) is present in ~50% of HFrEF patients and independently impairs exercise capacity and outcomes. IV ferric carboxymaltose has been shown to improve symptoms, functional capacity, and quality of life (CONFIRM-HF, EFFECT-HF). AFFIRM-AHF showed a trend toward reduced HF hospitalizations. IRONMAN showed a reduction in HF hospitalizations and CV death. Oral iron is inadequate due to poor absorption in HF patients (gut edema, hepcidin elevation).

Agent Indication Dose Key Trial Mortality Benefit?
Hydralazine/ISDN Self-identified Black patients (NYHA III-IV) or ACEi/ARB/ARNI intolerant 37.5/20 mg TID → 75/40 mg TID A-HeFT Yes (43% RRR in A-HeFT)
Ivabradine HR ≥70 bpm on max beta-blocker, sinus rhythm, LVEF ≤35% 5 mg BID → 7.5 mg BID SHIFT No (reduced composite endpoint)
Vericiguat Recent HF hospitalization, LVEF <45%, on optimized GDMT 2.5 → 5 → 10 mg daily VICTORIA No (reduced composite endpoint)
Digoxin Persistent HF symptoms or AF rate control 0.125-0.25 mg daily (target level 0.5-0.9 ng/mL) DIG No (reduced hospitalizations only)
Loop diuretics Volume overload / congestion Lowest effective dose for euvolemia No mortality RCT No (symptom management only)
IV ferric carboxymaltose Iron deficiency (ferritin <100 or TSAT <20%) Weight/Hgb-based IV dosing AFFIRM-AHF, IRONMAN Trend toward benefit; improves symptoms

Rapid Titration Protocol: A Practical 4-Week Strategy

Based on the STRONG-HF approach, the following protocol aims to initiate all four pillars simultaneously at low doses and uptitrate aggressively with close monitoring:

RAPID GDMT INITIATION PROTOCOL (4-WEEK)
  • Day 1 (Initiation): Start all four pillars at lowest doses — sacubitril/valsartan 24/26 mg BID + carvedilol 3.125 mg BID + spironolactone 12.5 mg daily + dapagliflozin 10 mg daily. Check baseline labs (BMP, CBC, NT-proBNP).
  • Week 1 (Visit 1): Check K+, creatinine, BP, HR, weight, symptoms. If tolerated: uptitrate sacubitril/valsartan to 49/51 mg BID and carvedilol to 6.25 mg BID.
  • Week 2 (Visit 2): Recheck labs. If tolerated: uptitrate sacubitril/valsartan to 97/103 mg BID, carvedilol to 12.5 mg BID, spironolactone to 25 mg daily.
  • Week 4 (Visit 3): Recheck labs. If tolerated: uptitrate carvedilol to 25 mg BID (target). Reassess symptoms, volume status, and NT-proBNP. Continue monitoring every 1-2 months.
  • Monitoring thresholds: Hold uptitration if SBP <100, HR <55, K+ >5.0, creatinine rise >30% from baseline, or symptomatic hypotension/bradycardia.
Clinical Pearl: In STRONG-HF, the rapid initiation group had more frequent early follow-up visits (week 1, 2, 3, and 6) with mandatory lab checks at every visit. This close monitoring is the key safety measure that enables aggressive titration. Without the infrastructure for frequent follow-up, a more conservative 6-8 week titration may be safer. Telehealth visits with home BP/HR/weight monitoring can serve as a practical compromise.

Key References

  1. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. DOI: 10.1056/NEJMoa1409077
  2. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. DOI: 10.1056/NEJMoa1911303
  3. Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised trial. Lancet. 2022;400(10367):1938-1952. DOI: 10.1016/S0140-6736(22)02076-1
  4. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263-e421. DOI: 10.1016/j.jacc.2021.12.012
  5. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. DOI: 10.1056/NEJMoa2107038